Found: 359
Select item for more details and to access through your institution.
New pharmaceuticals in inflammatory bowel disease.
- Published in:
- Gastroenterology Review / Przegląd Gastroenterologiczny, 2015, v. 10, n. 2, p. 57, doi. 10.5114/pg.2015.52702
- By:
- Publication type:
- Article
Assessment of Vedolizumab Disease‐Drug‐Drug Interaction Potential in Patients With Inflammatory Bowel Diseases.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 7, p. 734, doi. 10.1002/cpdd.891
- By:
- Publication type:
- Article
Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.905133
- By:
- Publication type:
- Article
A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy Individuals.
- Published in:
- Drugs in R&D, 2020, v. 20, n. 4, p. 359, doi. 10.1007/s40268-020-00324-1
- By:
- Publication type:
- Article
The Potential of Epigallocatechin-3-gallate (EGCG) as Complementary Medicine for the Treatment of Inflammatory Bowel Disease.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 5, p. 748, doi. 10.3390/ph16050748
- By:
- Publication type:
- Article
Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 2, p. 239, doi. 10.3390/ph16020239
- By:
- Publication type:
- Article
Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Intestinal Protein Characterisation of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in Inflammatory Bowel Disease (IBD) and Fatal COVID-19 Infection.
- Published in:
- Inflammation, 2022, v. 45, n. 2, p. 567, doi. 10.1007/s10753-021-01567-z
- By:
- Publication type:
- Article
Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study.
- Published in:
- Journal of Digestive Diseases, 2024, v. 25, n. 4, p. 230, doi. 10.1111/1751-2980.13270
- By:
- Publication type:
- Article
Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab.
- Published in:
- Journal of Digestive Diseases, 2024, v. 25, n. 2, p. 91, doi. 10.1111/1751-2980.13261
- By:
- Publication type:
- Article
Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Interstitial Granulomatous Dermatitis as an Adverse Reaction to Vedolizumab.
- Published in:
- Cutis, 2022, v. 109, n. 3, p. 167, doi. 10.12788/cutis.0467
- By:
- Publication type:
- Article
Cutaneous Chaetomium globosum Infection in a Vedolizumab-Treated Patient.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Differences in Whole-Blood Transcriptional Profiles in Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-Responders †.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 6, p. 5820, doi. 10.3390/ijms24065820
- By:
- Publication type:
- Article
Serological Biomarkers of Extracellular Matrix Turnover and Neutrophil Activity Are Associated with Long-Term Use of Vedolizumab in Patients with Crohn's Disease.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 15, p. 8137, doi. 10.3390/ijms23158137
- By:
- Publication type:
- Article
Article Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease--A Pilot Study.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 8, p. 1827, doi. 10.3390/ijms18081827
- By:
- Publication type:
- Article
Severe erosive gingivostomatitis in a patient treated by vedolizumab.
- Published in:
- Dermatology Online Journal, 2020, v. 26, n. 10, p. 1, doi. 10.5070/d32610050468
- By:
- Publication type:
- Article
Severe erosive gingivostomatitis in a patient treated by vedolizumab.
- Published in:
- Dermatology Online Journal, 2020, v. 26, n. 9, p. 1
- By:
- Publication type:
- Article
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Impact of Cigarette Smoking on the Risk of Osteoporosis in Inflammatory Bowel Diseases.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 7, p. 1515, doi. 10.3390/jcm10071515
- By:
- Publication type:
- Article
Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 6, p. 1242, doi. 10.3390/jcm10061242
- By:
- Publication type:
- Article
Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 7, p. 2126, doi. 10.3390/jcm9072126
- By:
- Publication type:
- Article
Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 5, p. 1323, doi. 10.3390/jcm9051323
- By:
- Publication type:
- Article
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 2, p. 385, doi. 10.3390/jcm9020385
- By:
- Publication type:
- Article
COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study.
- Published in:
- Vaccines, 2022, v. 10, n. 8, p. 1166, doi. 10.3390/vaccines10081166
- By:
- Publication type:
- Article
Nodular vasculitis during treatment with vedolizumab in a patient with ulcerative colitis.
- Published in:
- Australasian Journal of Dermatology, 2022, v. 63, n. 1, p. 131, doi. 10.1111/ajd.13754
- By:
- Publication type:
- Article
Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-28907-3
- By:
- Publication type:
- Article
Vedolizumab for acute gastrointestinal graft-versushost disease: A systematic review and meta-analysis.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1025350
- By:
- Publication type:
- Article
A broad cuproptosis landscape in inflammatory bowel disease.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1031539
- By:
- Publication type:
- Article
Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 11, p. 1312, doi. 10.1111/apt.18006
- By:
- Publication type:
- Article
Letter: Comparing first‐line infliximab and vedolizumab for ulcerative colitis—it depends on how you use the drug. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 1, p. 142, doi. 10.1111/apt.17796
- By:
- Publication type:
- Article
Letter: Comparing first‐line infliximab and vedolizumab for ulcerative colitis—it depends on how you use the drug.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 1, p. 140, doi. 10.1111/apt.17770
- By:
- Publication type:
- Article
Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis—Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1243, doi. 10.1111/apt.17750
- By:
- Publication type:
- Article
Editorial: Is vedolizumab the preferred biologic therapy for biologic‐naïve patients with ulcerative colitis?
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Real‐world effectiveness of vedolizumab compared to anti‐TNF agents in biologic‐naïve patients with ulcerative colitis: A two‐year propensity‐score‐adjusted analysis from the prospective, observational VEDO<sub>IBD</sub>‐study
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 4, p. 429, doi. 10.1111/apt.17616
- By:
- Publication type:
- Article
Systematic review and meta‐analysis of randomised controlled trials: Medical therapies for the treatment and prevention of pouchitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 3, p. 268, doi. 10.1111/apt.17568
- By:
- Publication type:
- Article
Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 2, p. 262, doi. 10.1111/apt.17610
- By:
- Publication type:
- Article
Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure? Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 6, p. 735, doi. 10.1111/apt.17405
- By:
- Publication type:
- Article
Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients—authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 6, p. 743, doi. 10.1111/apt.17407
- By:
- Publication type:
- Article
Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 6, p. 741, doi. 10.1111/apt.17395
- By:
- Publication type:
- Article
Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 6, p. 676, doi. 10.1111/apt.17305
- By:
- Publication type:
- Article
Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure?
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease—authors' reply.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 5, p. 524, doi. 10.1111/apt.17277
- By:
- Publication type:
- Article
The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population‐based, longitudinal study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 10, p. 1453, doi. 10.1111/apt.17217
- By:
- Publication type:
- Article
Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 56, n. 6, p. 1044, doi. 10.1111/apt.17153
- By:
- Publication type:
- Article
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non‐elderly patients with inflammatory bowel disease—the IG‐IBD LIVE study. Authors' reply.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non‐elderly patients with inflammatory bowel disease ‐ the IG‐IBD LIVE study.
- Published in:
- 2022
- By:
- Publication type:
- Editorial